Loading...
NPI 1245344605 · St Louis, MO · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Levent Akduman is a ophthalmology physician provider located in St Louis, Missouri. This profile covers 31 Medicare and 11 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Levent Akduman |
| Address | 1755 S Grand |
| City | St Louis |
| State | MO |
| ZIP | 63104 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | August 19, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.1M |
| Medicaid | $1.4M |
This provider bills substantially to both Medicare and Medicaid, with reported lifetime Medicare revenue of $3.1M and Medicaid revenue of $1.4M, so they are not a single‑payer practice but have a materially larger Medicare footprint. The NPI was enumerated 2006-08-19 (~20 years ago), indicating a long-established practice that has built revenue across both public payers over time.
Revenue is highly concentrated by code within each payer: the top 3 Medicare codes account for 78.5% of Medicare revenue and the top 3 Medicaid codes account for 93.3% of Medicaid revenue. That concentration signals reliance on a small set of procedures and drugs to generate the majority of public‑payer income.
Clinical mix and service line point to a retina‑focused ophthalmology operation: Medicare top drivers include J0178 (aflibercept) at $1.7M revenue (54.0%) and J2777 (faricimab) (16.8%), alongside 67028 intravitreal injection procedures (7.8%). On the Medicaid side, 67028 (4.7K claims, 69.2%) and J9035 (bevacizumab, 19.8%) dominate, and the presence of high volumes for 92134 and 92250 supports in‑house retinal imaging and diagnostics to manage injection clinics.
There is a payer‑driven difference in drug mix: Medicare revenue is concentrated in J0178 (aflibercept) and J2777 (faricimab), while Medicaid volume is driven heavily by J9035 (bevacizumab) and 67028 injections. This pattern suggests the practice administers different anti‑VEGF agents by payer, consistent with common clinical and reimbursement incentives across Medicare and state Medicaid.
Competitive standing varies by code and payer: for Medicare, J0178 is labeled in the dataset as a "typical, unremarkable volume for this code" despite ranking in the 89th percentile, whereas 67028 and J9035 are documented as "notably above typical national volume," and 92250 is marked an "extreme outlier, far above typical national volume," indicating locally exceptional imaging and some injection volumes. For Medicaid, 67028 ranks #2 in‑state (97th percentile; notably above typical state volume) and J9035 ranks #1 in‑state (100th percentile) but is labeled "typical, unremarkable volume for this code" in the source, which overall positions the provider as a leading state‑level injector for Medicaid patients.
Operationally, the practice appears to run a high‑throughput injection clinic: Medicaid shows 4.7K claims for 67028 and 3.7K claims for J9035, while Medicare shows 2.4K claims for J0178 and 2.6K claims for 67028. These claim volumes, combined with elevated imaging (92134, 92250), imply integrated diagnostic and therapeutic retina services that support frequent follow‑up and repeat treatment visits.
The concentration in a few high‑revenue codes creates exposure to payer policy or treatment‑pattern shifts: with the top 3 Medicare codes accounting for 78.5% of Medicare revenue and the top 3 Medicaid codes accounting for 93.3% of Medicaid revenue, any changes to reimbursements for J0178, J9035, or 67028 (or clinical guidelines that change drug selection) could meaningfully affect overall revenue. At the same time, the practice’s long tenure (~20 years) and strong in‑state rankings on key injection and imaging codes suggest operational capacity to adapt within the retina service line.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
31 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 2,450 | $690 | $1.7M |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 18,060 | $30 | $523.7K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2,620 | $90 | $243.3K |
| Q5124 | Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | 680 | $170 | $116.3K |
| J2778 | Injection, ranibizumab, 0.1 mg | 520 | $180 | $95.5K |
| J9035 | Injection, bevacizumab, 10 mg | 1,340 | $50 | $72.2K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 780 | $90 | $69K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,000 | $30 | $57.9K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 310 | $160 | $49K |
| 92250 | Code 92250 describes the taking of fundus photographs, that is, photographs of the posterior segment of the inner aspect of the eye, to document alterations in the optic nerve head, retinal vessels,… | 1,470 | $30 | $41K |
Showing 1–10 of 31
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 31 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
31 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 3 | 60 | 820 | $690 | $683.3K |
| J2777 | 12 | 50 | 11,730 | $30 | $388.9K |
| J2778 | 14 | 20 | 540 | $180 | $203.8K |
| Q5124 | 2 | 10 | 680 | $170 | $110.5K |
| 66984 | 201 | 420 | 50 | $390 | $74K |
| 67028 | 4 | 80 | 600 | $90 | $69.7K |
| 67040 | 3 | 10 | 30 | $1,000 | $38.1K |
| J7312 | 2 | 10 | 170 | $160 | $33.8K |
| 67042 | 6 | 30 | 20 | $1,070 | $26.8K |
| 67036 | 10 | 20 | 20 | $980 | $25.5K |
Showing 1–10 of 31
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
11 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 4,710 | $200 | $955.7K |
| J9035 | Injection, bevacizumab, 10 mg | 3,690 | $70 | $272.8K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 3,740 | $20 | $59.8K |
| 92250 | Code 92250 describes the taking of fundus photographs, that is, photographs of the posterior segment of the inner aspect of the eye, to document alterations in the optic nerve head, retinal vessels,… | 1,830 | $30 | $53K |
| J0178 | Injection, aflibercept, 1 mg | 10 | $990 | $13.9K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 350 | $30 | $10.6K |
| 92226 | N/A | 460 | $20 | $10K |
| 92235 | The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken… | 90 | $30 | $3K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 90 | $20 | $1.3K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 20 | $30 | $390 |
Showing 1–10 of 11
How this provider's Medicaid billing volume and revenue compare to other Missouri providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Missouri median
11 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 3,990 | 4,310 | 300 | $60 | $110.8K |
| J0178 | Injection, aflibercept, 1 mg | 4 | 10 | 280 | $290 | $106.9K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2 | 30 | 290 | $90 | $75.9K |
| J9035 | Injection, bevacizumab, 10 mg | 1 | 10 | 730 | $60 | $73.9K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 215 | 560 | 190 | $60 | $36K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 71 | 120 | 120 | $40 | $23.9K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 6 | 60 | 340 | $20 | $19.3K |
| 92226 | N/A | 10 | 20 | 430 | $20 | $7.9K |
| 92250 | Code 92250 describes the taking of fundus photographs, that is, photographs of the posterior segment of the inner aspect of the eye, to document alterations in the optic nerve head, retinal vessels,… | 2 | 50 | 70 | $20 | $5.1K |
| 92235 | The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken… | 2 | 10 | 40 | $50 | $3.2K |
Showing 1–10 of 11
Other providers in the same ZIP code as Levent Akduman, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Ssm Cardinal Glennon Children's Hospital | MO | Children's Hospital | $0 | $52.6M |
| Ssm-sluh Inc | MO | General Acute Care Hospital | $0 | $20.6M |
| Ssm Health Care Group | MO | Internal Medicine Physician | $0 | $17.3M |
| Affinia Healthcare | MO | Federally Qualified Health Center (FQHC) | $0 | $4.2M |
| Southside Wellness Center Inc | MO | Personal Care Attendant | $0 | $3.8M |
| Shamseldeen Mahmoud | MO | Neuroradiology Physician | $109.5K | $474K |
| Kristin Smith | MO | Dermatopathology Physician | $451.5K | $12.4K |
| Nicole Burkemper | MO | Dermatology Physician | $237K | $51.7K |
| M Yadira Hurley | MO | Dermatopathology Physician | $242K | $38.4K |
| Abdalla Hassan | MO | Interventional Cardiology Physician | $244K | $8.1K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.